Sign in
Download Opera News App

Stock-investment

3 New Catalysts for Palantir's High-Flying Stock

3 New Catalysts for Palantir's High-Flying Stock

3 New Catalysts for Palantir's High-Flying Stock Palantir's (NYSE: PLTR) stock has roughly tripled in price since its direct listing three months ago. Interest in the data-mining firm's stock was initially tepid due to its controversial business model, heavy dependence on government contracts, lack of profits, and ongoing insider sales. On Dec. 8, Palantir said the U.S. Food and Drug Administration (FDA)...

Read Full Story
FDA NYSE Palantir U.S. Food and Drug Administration